Sanofi (NASDAQ:SNY) Shares Sold by NewSquare Capital LLC

NewSquare Capital LLC decreased its holdings in Sanofi (NASDAQ:SNY) by 0.3% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 110,714 shares of the company’s stock after selling 386 shares during the period. NewSquare Capital LLC’s holdings in Sanofi were worth $6,065,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its position in shares of Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock worth $522,991,000 after purchasing an additional 5,091,304 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Sanofi in the fourth quarter worth about $135,933,000. Boston Partners grew its stake in Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after purchasing an additional 2,501,073 shares in the last quarter. Magnetar Financial LLC boosted its stake in Sanofi by 104.3% during the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Sanofi by 969.6% during the 4th quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company’s stock worth $45,850,000 after acquiring an additional 861,770 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

Shares of SNY opened at $50.47 on Monday. The firm has a market capitalization of $123.78 billion, a PE ratio of 20.27, a P/E/G ratio of 1.01 and a beta of 0.50. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a 50-day moving average price of $51.71 and a 200 day moving average price of $52.00. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter last year, the business earned $1.78 earnings per share. On average, sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a $2.0369 dividend. This is a positive change from Sanofi’s previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. This represents a dividend yield of 3.1%. Sanofi’s dividend payout ratio is 57.14%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 28th. BNP Paribas started coverage on Sanofi in a report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price for the company. Finally, Morgan Stanley set a $56.00 price target on Sanofi in a research report on Monday, June 2nd. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.